Mexico pharmaceutical industry and healthcare spending

Mexico is facing significant financial and logistical challenges regarding its pharmaceutical sector and public health infrastructure. The federal government has proposed a new labeling requirement for medicines under the 2027–2028 consolidated procurement program. Rafael Gual, director general of Canifarma, warned that this mandate could cost the industry approximately 10 billion pesos and stated, “Sí, ralentizaría totalmente el proceso de entrega de los medicamentos,” suggesting it would “tener un costo brutal para la industria.”

Simultaneously, the costs for the nation’s Megafarmacia project are projected to rise to 17.635 billion pesos by 2026, a 39% increase over 2024 estimates. Data from the Secretaría de Hacienda y Crédito Público indicates discrepancies in previous cost reports, noting that while initial estimates were lower, the actual investment to start operations was 3.948 billion pesos. Reports also highlight infrastructure concerns at the Huehuetoca site, including a sinkhole that was reportedly blocked with rubble rather than repaired.